All-oral Direct-acting Antiviral Regimens in HIV/Hepatitis C Virus-coinfected Patients with Cirrhosis Are Efficient and Safe: Real-life Results from the Prospective ANRS CO13-HEPAVIH Cohort

Clinical Infectious Diseases

Volumn 63, Issue 6, 2016, Pages 763-770

  Sogni, Philippe ^a,b,c   Gilbert, Camille ^d   Lacombe, Karine ^e,f   Piroth, Lionel ^g,h   Rosenthal, Eric ^i,j   Miailhes, Patrick ^k   Gervais, Anne ^l   Esterle, Laure ^d   Chas, Julie ^m   Poizot Martin, Isabelle ⁿ   Dominguez, Stcrossed D Signphanie ^o   Simon, Anne ^p   Morlat, Philippe ^q,r   Neau, Didier ^r,s   Zucman, David ^t   Bouchaud, Olivier ^u,v   Lascoux Combe, Caroline ^w   Bani Sadr, Firouzcrossed D Sign© ^x,y   Alric, Laurent ^z,aa   Goujard, Ccrossed D Sign©cile ^o,ab   Vittecoq, Daniel ^o,ab   Billaud, Eric ^ac   Aumaître, Hugues ^ad   BouCrossed D Sign©, François ^o,ab   Valantin, Marc Antoine ^p   Dabis, François ^d,r,ae   Salmon, Dominique ^a,c   Wittkop, Linda ^d,r,ae   more..

^a Hôpital Cochin ^*  (France)

^b INSTITUT PASTEUR   (France)

^c UniversitCrossed D e' Paris Descartes ^*  (France)

^d INSERM   (France)

^e HÔPITAL SAINT ANTOINE   (France)

^f SORBONNE UNIVERSITÉ   (France)

^g DIJON UNIVERSITY HOSPITAL   (France)

^h UNIVERSITÉ DE BOURGOGNE   (France)

ⁱ CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^j UNIVERSITÉ CÔTE D'AZUR   (France)

^k CROIX ROUSSE HOSPITAL   (France)

^l BICHAT HOSPITAL   (France)

^m HÔPITAL TENON   (France)

ⁿ Hopitaux Sud AP HM   (France)

^o ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^p PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^q HÔPITAL SAINT ANDRÉ   (France)

^r UNIVERSITÉ DE BORDEAUX   (France)

^s HÔPITAL PELLEGRIN   (France)

^t FOCH HOSPITAL   (France)

^u AVICENNE HOSPITAL   (France)

^v UNIVERSITÉ PARIS 13   (France)

^w SAINT LOUIS HOSPITAL   (France)

^x REIMS UNIVERSITY HOSPITAL   (France)

^y UniversitCrossed D e' de Reims   (France)

^z CHU PURPAN   (France)

^aa UNIVERSITÉ PAUL SABATIER   (France)

^ab UNIVERSITÉ PARIS SACLAY   (France)

^ac NANTES UNIVERSITY HOSPITAL   (France)

^ad Centre Hospitalier de Perpignan   (France)

^ae BORDEAUX UNIVERSITY HOSPITAL   (France)

more..

Author keywords

cirrhosis; direct acting antiviral treatment; hepatitis C virus (HCV); human immunodficiency virus (HIV); virologic response

Indexed keywords

ASUNAPREVIR; BOCEPREVIR; DACLATASVIR; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; INTEGRASE INHIBITOR; INTERFERON; LEDIPASVIR; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PEGINTERFERON; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR; TELAPREVIR; VIRUS RNA; ANTIVIRUS AGENT;

ADULT; ANEMIA; ANTIVIRAL THERAPY; ARTHRALGIA; ARTICLE; BRONCHITIS; CANDIDIASIS; CARDIOVASCULAR DISEASE; CD4 LYMPHOCYTE COUNT; CHILD PUGH SCORE; COHORT ANALYSIS; COUGHING; DECOMPENSATED LIVER CIRRHOSIS; DIGESTIVE SYSTEM FUNCTION DISORDER; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FATIGUE; FEMALE; FOLLOW UP; GYNECOMASTIA; HEADACHE; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 2; HEPATITIS C VIRUS GENOTYPE 3; HEPATITIS C VIRUS GENOTYPE 4; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSOMNIA; KIDNEY FAILURE; LIPOHYPERTROPHY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MIXED INFECTION; MOOD DISORDER; MUCOSA INFLAMMATION; MULTICENTER STUDY; MYALGIA; NONHUMAN; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PUBLIC HEALTH SERVICE; SKIN DISEASE; TREATMENT DURATION; TREATMENT OUTCOME; COMPLICATION; HEPACIVIRUS; SUSTAINED VIROLOGIC RESPONSE;

ANTIVIRAL AGENTS; COHORT STUDIES; FEMALE; HEPACIVIRUS; HEPATITIS C; HIV INFECTIONS; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RIBAVIRIN; SOFOSBUVIR; SUSTAINED VIROLOGIC RESPONSE; TREATMENT OUTCOME;

EID: 84995505955     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciw379     Document Type: Article

References (33)

1. Lewden C, Bouteloup V, De Wit S, et al. All-cause mortality in treated HIV-infected adults with CD4 >/=500/mm3 compared with the general population: evidence from a large European observational cohort collaboration. Int J Epidemiol 2012; 41:433-45.
2. May MT, Ingle SM. Life expectancy of HIV-positive adults: a review. Sex Health 2011; 8:526-33.
3. Hernando V, Perez-Cachafeiro S, Lewden C, et al. All-cause and liver-related mortality in HIV positive subjects compared to the general population: differences by HCV co-infection. J Hepatol 2012; 57:743-51.
4. Chen TY, Ding EL, Seage III GR, Kim AY. Meta-analysis: increased mortality associated with hepatitis C in HIV-infected persons is unrelated to HIV disease progression. Clin Infect Dis 2009; 49:1605-15.
5. Morlat P, Roussillon C, Henard S, et al. Causes of death among HIV-infected patients in France in 2010 (national survey): trends since 2000. AIDS 2014; 28:1181-91.
6. Rosenthal E, Roussillon C, Salmon-Ceron D, et al. Liver-related deaths in HIVinfected patients between 1995 and 2010 in France: the Mortavic 2010 study in collaboration with the Agence Nationale de Recherche sur le SIDA (ANRS) EN 20 Mortalite 2010 survey. HIV Med 2015; 16:230-9.
7. Loko MA, Salmon D, Carrieri P, et al. The French national prospective cohort of patients co-infected with HIV and HCV (ANRS CO13 HEPAVIH): early findings, 2006-2010. BMC Infect Dis 2010; 10:303.
8. McHutchison JG, Lawitz EJ, Shiffman ML, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009; 361:580-93.
9. Soriano V, Puoti M, Sulkowski M, et al. Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel. AIDS 2007; 21:1073-89.
10. Mira JA, Garcia-Rey S, Rivero A, et al. Response to pegylated interferon plus ribavirin among HIV/hepatitis C virus-coinfected patients with compensated liver cirrhosis. Clin Infect Dis 2012; 55:1719-26.
11. Sulkowski M, Pol S, Mallolas J, et al. Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial. Lancet Infect Dis 2013; 13:597-605.
12. Hezode C, Fontaine H, Dorival C, et al. Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis. Gastroenterology 2014; 147:132-42 e4.
13. Cotte L, Braun J, Lascoux-Combe C, et al. Telaprevir for HIV/hepatitis C viruscoinfected patients failing treatment with pegylated interferon/ribavirin (ANRS HC26 TelapreVIH): an open-label, single-arm, phase 2 trial. Clin Infect Dis 2014; 59:1768-76.
14. Miailhes P, Gilbert C, Lacombe K, et al. Triple therapy with boceprevir or telaprevir in a European cohort of cirrhotic HIV/HCV genotype 1-coinfected patients. Liver Int 2015; 35:2090-9.
15. Salmon D, Bani-Sadr F, Gilbert C, et al. HCV viral load at baseline and at week 4 of telaprevir/boceprevir based triple therapies are associated with virological outcome in HIV/hepatitis C co-infected patients. J Clin Virol 2015; 73:32-5.
16. Arends JE, van der Meer JT, Posthouwer D, et al. Favourable SVR12 rates with boceprevir or telaprevir triple therapy in HIV/HCV coinfected patients. Neth J Med 2015; 73:324-30.
17. Sulkowski MS, Naggie S, Lalezari J, et al. Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection. JAMA 2014; 312:353-61.
18. Molina JM, Orkin C, Iser DM, et al. Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, openlabel, non-randomised, phase 3 study. Lancet 2015; 385:1098-106.
19. Wyles DL, Ruane PJ, Sulkowski MS, et al. Daclatasvir plus sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med 2015; 373:714-25.
20. Naggie S, Cooper C, Saag M, et al. Ledipasvir and sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med 2015; 373:705-13.
21. SulkowskiMS, Eron JJ, Wyles D, et al. Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial. JAMA 2015; 313:1223-31.
22. Winnock M, Bani-Sadr F, Pambrun E, et al. Factors associated with guidelinebased hepatitis C virus (HCV) treatment initiation in HIV/HCV-coinfected patients: role of comorbidities and physicians' perceptions. HIV Med 2013; 14:430-6.
23. American Association for the Study of Liver Diseases/Infectious Diseases Society of America HCV Guidance Panel. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, treating adults infected with hepatitis C virus. Hepatology 2015; 62:932-54.
24. European Association for the Study of the Liver. EASL recommendations on treatment of Hepatitis C 2015. J Hepatol 2015; 63:199-236.
25. Chazouillères O, Fontaine H, Hanslik B, et al. Recommandations AFEF sur la prise en charge des hépatites virales C. Paris: Association Francaise pour l'Etude du Foie, 2015. Available at: www. afef. asso. fr.
26. Rodriguez-Torres M, Gaggar A, Shen G, et al. Sofosbuvir for chronic hepatitis C virus infection genotype 1-4 in patients coinfected with HIV. J Acquir Immune Defic Syndr 2015; 68:543-9.
27. Sulkowski MS, Jacobson IM, Nelson DR. Daclatasvir plus sofosbuvir for HCV infection. N Engl J Med 2014; 370:1560-1.
28. Saxena V, Nyberg L, Pauly M, et al. Safety and efficacy of simeprevir/sofosbuvir in hepatitis C-infected patients with compensated and decompensated cirrhosis. Hepatology 2015; 62:715-25.
29. Charlton M, Everson GT, Flamm SL, et al. Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology 2015; 149:649-59.
30. van der Meer AJ, Veldt BJ, Feld JJ, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. Jama 2012; 308:2584-93.
31. Limketkai BN, Mehta SH, Sutcliffe CG, et al. Relationship of liver disease stage and antiviral therapy with liver-related events and death in adults coinfected with HIV/HCV. JAMA 2012; 308:370-8.
32. Klein MB, Rollet-Kurhajec KC, Moodie EE, et al. Mortality in HIV-hepatitis C coinfected patients in Canada compared to the general Canadian population (2003-2013). AIDS 2014; 28:1957-65.
33. Berenguer J, Zamora FX, Carrero A, et al. Effects of sustained viral response in patients with HIV and chronic hepatitis C and nonadvanced liver fibrosis. J Acquir Immune Defic Syndr 2014; 66:280-7.